We have isolated the rat ortholog of EFP1 (EF-hand binding protein 1) as a novel interaction partner of the pro-apoptotic protein Par-4 (prostate apoptosis response-4). Rat EFP1 contains two thioredoxin domains, the COOH-terminal one harboring a CGFC motif, and has a similar protein domain structure as members of the protein disulfide isomerase (PDI) family. In REF52.2 and CHO cells, EFP1 colocalized with the endoplasmic reticulum (ER) marker PDI. Furthermore, EFP1 possesses catalytic activity as demonstrated by an insulin disulfide reduction assay. Western blot analysis revealed two EFP1 protein bands of approximately 136 and 155 kDa, representing different glycosylation states of the protein. Complex formation between EFP1 and Par-4 was confirmed in vitro and in vivo by co-immunoprecipitation, dot blot overlay and pull-down experiments. In CHO cells, coexpression of EFP1 and Par-4 resulted in enhanced Par-4-mediated apoptosis, which required the catalytic activity of EFP1. Interestingly, EFP1 was specifically upregulated in NIH3T3 cells after induction of ER stress by thapsigargin, tunicamycin, and brefeldin A, but not by agents that induce oxidative stress or ER-independent apoptosis. Furthermore, we could show that the induction of apoptosis by Ca 2+ stress-inducing agents was significantly decreased after siRNA oligonucleotide-mediated knockdown of Par-4. Our data suggest that EFP1 might represent a cell-protective enzyme that could play an important role in the decision between survival and initiation of Par-4-mediated apoptosis.
Introduction
Conditions that alter the endoplasmic reticulum (ER) environment, commonly referred to as ER stress, can affect the efficiency of ER enzymes in performing their multiple tasks like protein folding and glycosylation. For example, extraordinarily high protein synthesis rates, as they occur in a virus-infected cell, can lead to an ER overload and to an accumulation of misfolded or unfolded proteins in the ER. Likewise, deregulated calcium homeostasis can disturb the function of the ER. In order to overcome such situations, genetic and molecular programs are activated to restore the function of the ER. A typical ER stress response initially consists of the attenuation of translation and activation of protein degradation pathways, while simultaneously the specific ER stress transcription factor ATF6 is activated, 1-3 which upregulates genes for ER chaperones like protein disulfide isomerase (PDI) and glucose-regulated protein 78/immunoglobulin binding protein (GRP78/BiP) to cope with the enhanced protein charge. 4, 5 Many stress-inducible ER chaperones, including PDI, glucose-regulated protein 94 (GRP94) and GRP78/BiP, also contain calcium binding domains that help maintaining or restoring the calcium gradient between the ER and the cytoplasm. [6] [7] [8] However, when the ER stress response fails to overcome the situation, signaling pathways are activated that induce execution of the programmed cell death, apoptosis. 9 To date, two major ER-specific apoptotic pathways are known. One of them initiates apoptosis by activation of caspases, cysteine-aspartate proteinases that play a central role in apoptosis. 10 Caspase-12 and caspase-4 have been described as ER-specific caspases that are activated during persistent ER stress. 11, 12 In addition, participation of other caspases has been suggested. 13, 14 A recent publication has demonstrated the dispensability of caspase-4 and caspase-12 for caspasedependent ER stress-mediated apoptosis, 15 suggesting the participation of other caspases. Thus, multiple redundant pathways may lead from ER stress to caspase-activation. ER stress-induced apoptosis can also be initiated independently of caspases, since an alternative apoptotic pathway in ER stress is triggered by GADD153/CHOP, an ER stressinducible transcription factor. 16 GADD153/CHOP alters the balance between the anti-apoptotic protein Bcl-2 and the pro-apoptotic Bax, 17 resulting in cytochrome C release from the mitochondria, a highly conserved pathway of apoptosis induction. 18 One of the proteins that has been implicated in ER stress-dependent apoptotic processes is the pro-apoptotic protein Par-4 (prostate apoptosis response-4). 19 The protein was originally discovered as the product of an early response gene in ionomycin-induced apoptosis of prostate cancer cells. 20 The mechanisms how Par-4 can induce or support apoptotic processes are versatile. We have demonstrated that Par-4 can bind to actin filaments and can induce apoptosis by sequestering nuclear proteins to the cytoskeleton like the pro-apoptotic serine/threonine kinase Dlk/ZIPK or the pro-apoptotic protein Amida. [21] [22] [23] In other cellular settings, Par-4 can act as a transcriptional co-repressor of the bcl-2 gene, 24 or as an inhibitor of PKB/Akt. 25 However, many aspects of Par-4-mediated apoptosis are still poorly understood. In an effort to identify novel interaction partners of Par-4 that might serve as regulators or downstream effectors in Par-4-mediated apoptosis, we identified the rat ortholog of EF-hand binding protein 1 (EFP1) in a yeast two-hybrid screen. EFP1 was previously identified as an interaction partner of Duox, a protein involved in H 2 O 2 production in the thyroid. 26 We show that EFP1 is an ER-resident glycoprotein which possesses enzymatic activity in an insulin reduction assay and demonstrate that EFP1 is upregulated during ER stress. Coexpression of EFP1 and Par-4 resulted in enhanced EFP1/Par-4-mediated apoptosis, suggesting that EFP1 can trigger Par-4-mediated apoptosis.
Materials and methods generation of the cDnA library and yeast two-hybrid screening
The generation of the cDNA library and the yeast two-hybrid screening have been described previously. 27 Briefly, poly(A)
+ RNA was isolated from TZ103 cells, reversetranscribed, and inserted into the HybriZAP™ vector 28 using the ZAPExpress™ cDNA synthesis kit (Stratagene, La Jolla, CA). Two-hybrid screening was performed with Par-4 fused to the GAL4 DNA binding domain as bait. His and lacZ-positive clones were isolated and the cDNA inserts were further analyzed by cloning and sequencing.
Cloning of rat eFP1 cDnA and construction of plasmids
The rat EFP1 cDNA was amplified by RT-PCR using the E14-2 cDNA as template and the oligonucleotides 5´-GAAGGTCAAGTATCCAGGAGGCTGG-3´ and 5´-CCCAAGCTTATGTCGGAATGCGGA-3´ derived from the rat sequence EST XM220122.2. A C-terminally GFP-tagged full-length EFP1 cDNA construct (denoted EFP1-GFP) was generated by PCR with oligonucleotides 5´-C G G G A T C C T G A T G G C G C G C C A G -3´ a n d 5´-GCGGATCCAGTAAGTCTGTCCTGTTCTC-3´ and subcloned into the pEGFP-N1 expression vector using BamHI restriction sites (Clontech, Heidelberg, Germany). In order to generate a thioredoxin-domain II mutant of EFP1 (denoted EFP1 THX-) in which the cysteine residues of the CXXC motif were replaced by serines, site-directed mutagenesis was performed with the oligonucleotide pairs 5´-GAGTTTGCCACAATT-GTCGATGTG-3´, 5´-AGATGGGCTAAAGCCACTC-CACTG-3´, 5´-CAGTGGAGTGGCTTTAGCCCATCT-3´ and 5´-CCACCGGTGCTAAGTCTGTCCTGTTCTC-3´. A HindIII/BamHI cDNA restriction fragment of EFP1 was subcloned into the pcDNA6/Myc-His C vector (Invitrogen) to generate the construct EFP1-Myc. For the N-terminally His-tagged Par-4 cDNA construct (denoted His 6 -Par-4), the EcoRI fragment of the Par-4 cDNA from pCB6
+ -Par-4 29 was subcloned into the pPROEX TM HTa expression vector (Invitrogen GmbH, Karlsruhe, Germany). The construction of FLAG-Par-4 and the leucine zipper mutants FLAG-Par-4 L3A and His 6 -Par-4 L3A, carrying exchanges of leucines 295, 316, and 330 to alanines, has been described previously. Reverse Transcriptase (Invitrogen) using a 17mer oligo-dT primer. Expression of EFP1 was analyzed by PCR with oligonucleotides 5´-CCCCATGAGTGCTGTTTACATT-3´ and 5´-CGTACTGTTCCTAGGTAATC-3´ amplifying a 219 bp product of EFP1 and expression of GRP78/BiP with oligonucleotides 5´-GAAAGGATGGTTAATGATGCTGAG-3´ and 5´-GTCTTCAATGTCCGCATCCTG-3´ amplifying a 231 bp GRP78/BiP product. As internal control, a 309 bp GAPDH product was amplified with the oligonucleotides 5´-CGGTGTGAACGGATTTGGCCGTAT-3´ and 5´-AGCCTTCTCCATGGTGGTGAAGAC-3´.
Computer-assisted sequence analysis
To analyze the EFP1 structure in detail, multiple sequence alignments were performed with the ClustalW program. 30 For secondary structure predictions, the PredictProtein 31 and the Paircoil programs 32 were employed and the analyses of intracellular localization, posttranslational modifications, and signal peptide predictions were performed with the PSORT II, 33 NetPhos, 34 NetNGlyc, and SignalP programs. 35 Cell culture and transfection Hamster ovarian cells (CHO) were grown in Nutrient Mixture F12 (Sigma) with 10% FCS. Mouse immortal fibroblast cell line NIH3T3 was cultured in DMEM high glucose (Sigma) with 10% FCS and 1% glutamine. All cell culture media were supplemented with 100 units/ml penicillin and 100 µg/ml streptomycin. For transfection experiments, cells were seeded at 1000-3000 cells per mm 2 and transiently transfected using the jetPEI transfection reagent (PolyPlus, Illkirch, France) according to the manufacturer's protocol. For the generation of stable EFP1-expressing cell lines, CHO cells were transfected with EFP1-GFP expression vector and selected in the presence of 1 µg/ml Geneticin (G418) (Life Technologies, Inc, Karlsruhe, Germany). EFP1-GFP expressing colonies were selected and further cultured. For the Par-4 siRNA experiments, cells were transiently transfected with 20 pmol of Cy3-labeled 21-nucleotide double-stranded RNA molecules (Perbio Science Germany, Bonn) using the Lipofectamine 2000 reagent (Invitrogen) according to manufacturer's protocol. The following Par-4 siRNA oligonucleotides were employed: human Par-4 sense 5´-Cy3-GAUGCAAUUACACAACAG AUU-3´ and human Par-4 antisense 3´-UUCUACGUUAAUGU-GUUGUCU-Cy3-5´. 36 As mismatch control, siRNA oligonucleotides against rat Par-4 were used: rat Par-4 sense 5´-Cy3-GAUGCUAUCACACAGCAGAUU-3´ and rat Par-4 antisense 3´-UUCUACGAUAGUGUGUCGUCUCy3-5´. 48 h after transfection the cells were examined by fluorescence microscopy.
Immunofluorescence analysis
For immunofluorescence analysis, transfected cells were fixed with 3% paraformaldehyde and stained with the mouse monoclonal anti-c-Myc antibody 9E10 (1:200; Biomol GmbH, Hamburg, Germany), the rabbit polyclonal antiPar-4 antibody (1:5000; Santa Cruz Biotechnology Inc.) and the rabbit polyclonal anti-PDI antibody (1:4000, Biomol). As secondary antibodies, Cy3-conjugated goat anti-mouse IgG, Alexa488-conjugated goat anti-rabbit IgG and Cy3-conjugated goat anti rabbit IgGs (1:1000; Dianova, Hamburg, Germany) were used. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). Cells were examined 
Protein expression and purification
His 6 -Par-4, His 6 -Par-4 L3A, His 6 -EFP1 and His 6 -Amida were expressed in the E. coli strain BL21-CodonPlus DE3 (Stratagene). Bacteria were transformed with either expression vector and grown in LB-medium at 37 °C. Protein expression was induced in late log phase with 1 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) at 20-25 °C. Bacteria were harvested 5 h after induction and resuspended in NiNTA-buffer (50 mM KPO 4 -buffer, pH 8.0, 500 mM KCl, 10 mM imidazole, 5 mM 2-mercaptoethanol, 0.2% Tween, 1 mM PMSF). The cells were lysed with 1 mg/ml lysozyme for 15 min at 4 °C in the presence of 2 units/ml Benzonase (Merck Biosciences GmbH, Schwalbach, Germany). Lysates were solubilized by ultrasonic disruption and cleared from cell debries by centrifugation. Recombinant proteins were purified using a NiNTA-matrix (IBA GmbH, Göttingen, Germany) essentially according to the manufacturer's instructions. The samples were further purified on a NAP-5 column (Amersham), eluted in low salt buffer (20 mM Tris pH 7.0, 20 mM KCl) and concentrated on a Centricon Centrifugal Filter Unit with Ultracel YM-10 membrane (Millipore GmbH, Schwalbach, Germany).
sDs-PAge, Western Blot analysis and dot blot immunoassay
Cells were lysed in isotonic lysis buffer (10 mM NaPO4, pH 8.0, 140 mM NaCl, 3 mM MgCl 2 , 1 mM dithiothreitol, 0.5% Nonidet-P40 and 50 µM leupeptin). The cell lysates were subjected to SDS-PAGE according to standard procedures and electrophoretically transferred onto nitrocellulose membranes (Schleicher and Schuell GmbH, Dassel, Germany). The membranes were stained either with the mouse monoclonal anti-GFP antibody (1:2000, Clontech), the mouse monoclonal anti-FLAG M2 antibody (1:5000, Invitrogen), the rabbit polyclonal (1:5000) and mouse monoclonal (1:2000) antiPar-4 antibodies (Santa Cruz Biotechnology Inc., Heidelberg, Germany) or the mouse monoclonal anti-α-Tubulin antibody DM 1A (1:5000, Sigma). Bound antibodies were detected with peroxidase-conjugated secondary goat antimouse or goat anti-rabbit IgGs (1:5000, Dianova) using a SuperSignal ® West Pico chemoluminescence detection kit (Perbio Science GmbH, Bonn, Germany). For dot blots, 10-250 ng of purified recombinant His 6 -Amida protein, His 6 -EFP1 protein and bovine serum albumine (BSA) were spotted onto nitrocellulose membranes (Schleicher and Schuell). After blocking, membranes were incubated with 3 µg/ml of purified recombinant His 6 -Par-4 or His 6 -Par-4 L3A protein for 2 h and further processed as described above.
Insulin disulfide reduction assay
The assay was performed essentially as described by Holmgren 37 in quartz cuvettes in a final volume of 120 µl. Briefly, the incubation mixtures contained 3.9 µM of purified recombinant His 6 -EFP1 protein, His 6 -EFP1 THX-protein or recombinant thioredoxin protein from E. coli (Sigma), 0.1 M potassium phosphate (pH 7.0), 2 mM EDTA and 0.13 mM of bovine insulin (Sigma). The reaction was started by adding 0.33 mM dithiothreitol to the mixture. The rate of insulin reduction was measured spectrophotometrically at 650 nm for 100 min as turbidity formation from the precipitation of the insoluble free B chain.
In vitro translation and pulldown assay
In vitro translated [
35 S]-methionine labeled EFP1 was generated with the TNT-coupled reticulocyte lysate system (Promega GmbH, Mannheim, Germany) using the EFP1-Myc vector as template according to the manufacturer's protocol. The labeled EFP1 protein was incubated for 30 min at 4 °C with NiNTA beads in the absence or in the presence of purified His 6 -Par-4 wt or His 6 -Par-4 L3A, respectively. After washing with pull-down buffer (50 mM KPO 4 -buffer pH 7.0, 5 mM MgCl 2 , 100 mM KCl, 10 mM imidazole, 5% glycerol, 0.2% Tween, 1 mM PMSF), the bound proteins were eluted from the NiNTA beads with pull-down buffer containing 500 mM KCl. The eluted proteins were separated by SDS-PAGE and analyzed by autoradiography.
immunoprecipitation and endoglycosidase H treatment CHO cells stably expressing EFP1-GFP were transfected with FLAG-Par-4 or FLAG-vector alone as control. 24 h post-transfection, the cells were metabolically labeled with 250 µCi of [
35 S]methionine (10 mCi/ml, Amersham) per 9 cm-culture dish in methionine-free DMEM for 2 h. After labeling, the cells were washed with ice-cold phosphate-buffered saline (PBS) and lysed in isotonic lysis buffer. The lysates were subjected to immunoprecipitation with the rabbit polyclonal anti-GFP antibody (Clontech).
The antigen-antibody complexes were adsorbed to Protein A-Sepharose (Sigma), separated on 10% SDS-PAGE and further analyzed by autoradiography. For Endoglycosidase H (EndoH) experiments, HeLa cells were transfected with EFP1-GFP. 24 h after transfection cells were lysed in isotonic lysis buffer and the cell lysates subjected to immunoprecipitation as described above. The antigen-antibody-sepharose complex was treated with 1x denaturation buffer (0.5% SDS, 1% β-mercaptoethanol) at 100 °C for 10 minutes. The sepharose beads were sedimented and the supernatants were treated with EndoH (NEB) at 37 °C for 1 h according to the manufacturer's protocol. The samples were separated on 7.5% SDS-PAGE and further analyzed by Western blotting. 
Apoptosis assay

Results
Molecular cloning and sequence analysis of rat eFP1
In an attempt to identify new interaction partners of Par-4, we screened a rat cDNA library derived from the PNET cell line TZ103 27, 38 with full length Par-4 as bait. Seven positive clones were identified from histidine negative plates which were also positive for β-galactosidase expression. Sequence analysis revealed one clone with 100% identity to the rat cDNA XM220122.2, and BLAST analyses showed 94% and 90% sequence identity with the murine and human TXNDC11 (thioredoxin domain containing 11) cDNA sequences, encoding the EFP1. 26 Thus, our isolated cDNA clone comprising an open reading frame for 947 amino acids represented the rat ortholog of TXNDC11/EFP1.
Computer-assisted analysis of the EFP1 amino acid sequence (see Materials and methods) revealed that the predicted protein contains an N-terminal ER signal sequence or signal anchor sequence (aa 54-83) but no ER retention signal, a putative transmembrane domain (aa 60-76, see Figure 1A ), a putative NLS (aa 849-865), a leucine zipper motif (aa 834-855), an arginine rich sequence (aa 814-850), several putative phosphorylation sites for protein kinase C (PKC) and casein kinase 2 (CK2) as well as several N-glycosylation sites. The N-terminal portion of EFP1 is rich in glycine (35%, distributed between aa 5-50), thus facilitating N-myristoylation and a putative membrane localization of the protein. The presence of two thioredoxin domains ( Figure 1A , a, aa 104-207 and a', aa 659-764), whereas the C-terminal one contains a putative catalytically active CXXC motif ( 787 CGFC 790 ), classifies the protein as a novel member of the thioredoxin-related family. To gain more information about the domain structure of EFP1, the α-helix/β-strand composition was analyzed using the PredictProtein analysis program. Three variations of the thioredoxin fold alpha/beta pattern β-α-β-α-β-α-β-β-α 39,40 were identified, two of them spanning the two thioredoxin domains a and a', the other one adjacent to the first thioredoxin domain (b, Figure 1A ).
eFP1 is expressed in various tissues and cell lines
To analyze the expression of EFP1 at the transcriptional level, we hybridized a multiple tissue Northern blot with a probe corresponding to the EFP1 nucleotides 1583-2170. As depicted in Figure 1B Since the mRNA expression of GAPDH was quite variable between tissues, we performed a densiometric analysis of EFP1 and GAPDH bands detected after Northern blot analysis in Figure 1B using ImageJ software. The graph bar in Figure 1C shows the expression of EFP1 normalized to GAPDH. The densiometric analysis revealed that the relative expression level of EFP1 was highest in lung and spleen, less prominent in testis, liver and kidney and rather low in brain and heart. EFP1 expression was not detected in skeletal muscle.
In order to investigate the expression of EFP1 in transformed versus nontransformed cell lines, we performed semi-quantitative RT-PCR analysis with GAPDH as internal standard. We assayed the overall expression of EFP1 in nontransformed rat cells (REF52.2 fibroblasts, E14-2 fetal brain cells) and in transformed human prostate cancer cells (PC3), rat glioma cells (C6), rat PNET cell lines (TZ102, TZ103 and TZ107), and mouse neuroblastoma cells (N2A). As shown in Figure 1D (lanes 1-8) , all cell lines tested displayed the same expression level of EFP1 comparable to the uniform expression of the housekeeping gene GAPDH. These data suggested that the expression of EFP1 is not altered in the examined nontransformed and tumor cell lines.
Rat eFP1 is localized in the eR
To analyze the subcellular localization of rat EFP1 in mammalian cells, we examined C-terminally GFP-or Myc-tagged fusion proteins EFP1-GFP (Figure 2A , a-c) or EFP1-Myc (Figure 2A , d-f) in REF52.2 cells 24 h after transfection by confocal fluorescence microscopy. Since an ER localization has previously been described for the human ortholog of EFP1, 26 we employed in our studies an anti-PDI + RnA per lane from eight different rat tissues as indicated was probed with a cDnA fragment corresponding to rat eFP1 nucleotides 1583-2170 (upper panel). The same membrane was reprobed with a 32 P-labeled full-length gAPDH cDnA probe to quantify the eFP1 RnA expression relative to gAPDH expression (lower panel). C) Densiometric analysis of eFP1 expression normalized to gAPDH in multiple tissues. The densiometric analysis of the eFP1 and gAPDH bands detected after northern blot analysis in (B) was performed using imageJ software. D) expression of eFP1 and GAPDH in various cell lines analyzed by RT-PCR. cDNA from cell lines REF52.2, PC3, C6, E14-2, TZ102, TZ103, TZ107 and N2A (lanes 1-8) was amplified by PCR using conditions described under Experimental procedures. As internal standard, the house keeping gene GAPDH was amplified in the same PCR reactions. Abbreviations: eFP1, eF-hand binding protein 1; gAPDH, glyceraldehyde-3-phosphate dehydrogenase; RT-PCR, reverse transcriptase-polymerase chain reaction. 
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EFP1 is posttranslationally modified by n-glycosylation
When we transfected the EFP1-GFP construct into CHO cells and analyzed the expression of EFP1-GFP by Western blot analysis with a monoclonal anti-GFP antibody, we detected two protein bands of approximately 136 and 155 kDa. Detailed sequence analysis of EFP1 revealed that the protein comprises several potential N-glycosylation sites.
Since glycosylation can significantly alter the apparent molecular weight of a protein in SDS-PAGE analysis, we examined if glycosylation of EFP1 might be responsible for the two EFP1 protein variants observed by Western blot analysis. Hence, we subjected cell extracts from EFP1-GFP transfected HeLa cells to immunoprecipitation with a polyclonal anti-GFP antibody and treated the immunoprecipitated proteins with endoglycosidase H (EndoH). EndoH treatment specifically removes high-mannose type N-glycans which are typical for ER-resident proteins, but does not hydrolyze complex glycans that are generated by posttranslational modification in the Golgi apparatus. As control, we employed immunoprecipitated protein samples without EndoH treatment. Figure 2B, lane 1) . When the immunoprecipitated proteins were treated with Endo H, the 136 kDa EFP1-GFP protein band was detected, whereas the 155 kDa EFP1-GFP protein band was no longer visible ( Figure 2B, lane 3) . Thus, our results clearly demonstrated that EFP1 is a high mannose type-glycoprotein.
eFP1 possesses enzymatic activity
Since the C-terminal thioredoxin domain (THX II) of EFP1 contains an active site CXXC motif, typical for members of the thioredoxin (Trx) family, we next wanted to examine whether this thioredoxin domain of EFP1 is functional. For this purpose, we employed recombinant affinity purified His 6 -tagged EFP1 wt protein (designated His 6 -EFP1) and a His 6 -EFP1 THX-mutant carrying cysteine to serine substitutions in the active site CXXC motif in an insulin disulfide reduction assay. The quantitative assay was developed to measure the rate of insulin reduction spectrophotometrically at 650 nm as turbidity formation from the precipitation of the free insulin B chain. 37 As control, we included recombinant purified thioredoxin from E. coli (denoted E. coli THX) in our experiment, which has dithiol-disulfide-oxidoreductase activity and catalyzes the reduction of insulin by dithiothreitol. The recombinant His 6 -EFP1 wt protein ( Figures 2C and D , black squares) indeed catalyzes the reduction of insulin disulfides, although the kinetic of the reaction showed a markedly slower rate compared to THX from E. coli ( Figures 2C and D, black  circles) . That the catalytic activity of EFP1 was dependent on the putative active site motif CXXC in the THX II-domain of EFP1 was demonstrated with the recombinant His 6 -EFP1 THXmutant ( Figures 2C and D , white squares) which showed reduced insulin disulfide reduction activity compared to the His 6 -EFP1 wt protein ( Figures 2C and D, black squares) . However, the catalytic activity of the His 6 -EFP1 THX-mutant was not completely abolished compared to the control sample containing only dithiothreitol ( Figures 2C and D , white circles).
Upregulation of eFP1 in niH3T3 cells after eR stress
Because EFP1 is an ER-resident protein that possesses catalytic activity comparable to thioredoxin and structural similarities to members of the PDI family of ER chaperones, we speculated that EFP1 might be involved in the ER stress response. To test this hypothesis, we treated NIH3T3 cells with the ER stress-inducing agents tunicamycin and brefeldin A, with the Ca 2+ stress inducing agents thapsigargin and ionomycin, the latter also inducing ER stress. Furthermore, the cells were treated with the oxidative stress inductor H 2 O 2 , with staurosporine (STS), which induces apoptosis independently of ER stress, and with DMSO as control. The expression of EFP1 was examined by RT-PCR analysis ( Figure 2E , upper panel) with GAPDH as internal control ( Figure 2E, lower panel) . We also determined the expression of the ER stress marker GRP78/BiP ( Figure 2E, middle panel) . Treatment of NIH3T3 cells with either ionomycin, tunicamycin, thapsigargin, or brefeldin A ( Figure 2E, upper panel, lanes 2-5) , clearly resulted in the upregulation of EFP1. In analogy to these findings, the expression of the ER stress marker GRP78/BiP was also upregulated after ionomycin, tunicamycin, thapsigargin and brefeldin A treatment ( Figure 2E , middle panel, lanes 2-5). In contrast, neither EFP1 nor GRP78/BiP expression was affected after induction of oxidative stress by H 2 O 2 ( Figure 2E , lane 6) or after ER-independent induction of apoptosis by staurosporine ( Figure 2E , lane 7), thus demonstrating that the observed upregulation of EFP1 represents a specific ER stress-response.
eFP1 interacts with Par-4
Since the rat EFP1 cDNA was originally isolated in a yeast two-hybrid analysis with Par-4 as bait, we wanted to confirm the interaction of full length EFP1 with Par-4, both in vitro and in vivo. For the in vitro binding assays, Par-4 was expressed as His 6 -tagged fusion protein in E. coli, immobilized on NiNTA beads and incubated with 35 S-methioninelabeled in vitro-translated EFP1 protein. After stringent washing, the bound proteins were eluted from the NiNTAmatrix and analyzed by SDS-PAGE. In order to test whether the complex formation of EFP1 and Par-4 was dependent on a functional leucine zipper of Par-4, we also employed a His 6 -tagged leucine-zipper point mutant of Par-4 (denoted His 6 -Par-4 L3A), which contained three exchanges of leucine residues to alanines in the coiled coil interface. As shown in Figure 3A , EFP1 was pulled down together with His 6 -Par-4 wt ( Figure 3A , lane 3) and with His 6 -Par-4 L3A ( Figure 3A , lane 4), but not with NiNTA beads alone which served as negative control ( Figure 3A, lane 2) . Since equal amounts of EFP1 were eluted from the NiNTA-Par-4 wt and the NiNTA-Par-4 L3A matrixes, these results suggested that the interaction between EFP1 and Par-4 is not mediated by the leucine zipper of Par-4.
To further corroborate these findings, we performed dot-blot experiments with EFP1, Par-4 wt and Par-4 L3A.
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As positive control we included the novel Par-4 interaction partner Amida in our study, since it has been shown that complex formation between Par-4 and Amida requires a functional leucine-zipper of Par-4. 21 Hence, purified recombinant EFP1 and Amida proteins were spotted as dots on nitrocellulose membranes. Bovine serum albumin (BSA) served as negative control ( Figure 3B) . Next, the membranes were incubated with purified recombinant Par-4 ( Figure 3B, lanes 1-3) or Par-4 L3A ( Figure 3B , lanes [4] [5] [6] and subsequently stained with an anti-Par-4 antibody. Par-4 wt was detected in a concentration-dependent manner on both the Amida and EFP1 spotted membranes ( Figure 3B , lane 2 and 3) but no reaction with the BSA protein was observed ( Figure 3B To verify the interaction of EFP1 and Par-4 in vivo, cotransfection experiments with REF52.2, CHO and COS-1 cells were carried out with FLAG-Par-4 and EFP1-GFP. 24 h post-transfection, the cells were fixed, immunostained and analyzed by confocal fluorescence microscopy ( Figure 3C ). As expected, FLAG-Par-4 was clearly associated with actin filaments in REF52.2 cells and CHO cells ( Figure 3C , b and e), whereas Par-4 was diffusely distributed in COS-1 cells ( Figure 3C, h ), which lack a well organized actin cytoskeleton. In contrast, the EFP1-GFP construct showed no association with stress fibers in the FLAG-Par-4/EFP1-GFP coexpressing cells, but rather displayed an ER specific fluorescence staining ( Figure 3C, a, d and g ).
We then performed co-immunoprecipitation experiments with CHO cells stably expressing an EFP1-GFP fusion protein and transfected the cells with either FLAG-Par-4 or empty FLAG-vector as control. 24 h after transfection, the cells were metabolically labeled with [
35 S]-methionine and the cell lysates were subjected to immunoprecipitation with the rabbit polyclonal anti-GFP antibody. A protein of about 48 kDa representing the FLAG-Par-4 fusion protein was specifically coprecipitated with EFP1-GFP ( Figure 3D , lane 2) which could not be detected in mock-transfected cells ( Figure 3D, lane 1) . In summary, our data provide strong evidence that EFP1 and Par-4 interact under physiological conditions, although no colocalization was observed by immunofluorescence analysis.
Coexpression of eFP1 and Par-4 leads to enhanced apoptosis
Since we could show a physical interaction between EFP1 and the pro-apoptotic protein Par-4, we next asked whether EFP1 is also involved in Par-4-mediated apoptosis. To address this question, we co-transfected CHO cells with EFP1-GFP and FLAG-Par-4, fixed the cells 48 h post-transfection and stained the cells with the monoclonal anti-FLAG M2 antibody and with DAPI to visualize nuclei. Figure 4A (a-d) represents a cell co-transfected with EFP1-GFP and FLAG-Par-4 with normal morphology, whereas Figure 4A (e-h) represents a cell co-transfected with EFP1-GFP and FLAG-Par-4 with apoptotic morphology, ie, fragmented nuclei, condensed chromatin, and membrane blebbing.
In order to determine the percentage of apoptotic cells among the EFP1 and Par-4 co-expressing cells, we transfected CHO cells either with FLAG-Par-4, EFP1-GFP, EFP1 Figure 5A, lane 1, upper panel) . In order to verify that the different amounts of Par-4 detected in the samples were not due to unequal protein loading, immunostaining of the same membrane was performed with an α-tubulin antibody ( Figure 5A, lower panel) . The specificity of the Cy3-labeled double stranded human Par-4 siRNA oligonucleotides was further confirmed by confocal fluorescence microscopy (Figure 5 B) . In control cells, a strong fluorescence staining was detected with the polyclonal anti-Par-4 antibody ( Figure 5B, a) , in contrast to the human Par-4 siRNA oligonucleotide transfected cells ( Figure 5B, b) .
We next examined the effect of the siRNA oligonucleotide-mediated knockdown of endogenous Par-4 on ER The novel Par-4 interaction partner eFP1 is upregulated during eR stress Dovepress submit your manuscript | www.dovepress.com Dovepress stress-mediated apoptosis. Hence, we transfected HeLa cells with either human Par-4 siRNA or rat Par-4 siRNA as control, and treated the cells 48 h after transfection with agents inducing ER stress (ionomycin, thapsigargin, tunicamycin), with agents inducing ER stress independent apoptosis (etoposide and staurosporine) or with DMSO as control. Cells were fixed and stained with the rabbit polyclonal anti-Par-4 antibody and with DAPI to visualize nuclei. The percentage of apoptotic cells that showed fragmented nuclei, condensed chromatin and membrane blebbing was determined by fluorescence microscopy. As depicted in Figure 5C , treatment of HeLa cells with ionomycin induced apoptosis in about 17% of the cells ( Figure 5C , white column), whereas the siRNA oligonucleotide-mediated knockdown of Par-4 resulted in 3% apoptotic cells ( Figure 5C, black column) . The percentage of apoptotic cells after treatment with thapsigargin of about 30% ( Figure 5C , white column) was also significantly decreased to approximately 15% after siRNA-mediated Par-4 knockdown ( Figure 5C , black column) (p  0.01 for both agents in a two-tailed paired t-test). In contrast, no significant 
Discussion
In the present study, we report on the functional characterization of the rat ortholog of EFP1 and show that EFP1 is a novel interaction partner of the pro-apoptotic protein Par-4. The rat EFP1 protein shares 79% similarity with the human EFP1 protein, with the highest sequence identity between amino acids 51-304 and 564-767. According to secondary structure predictions, the first conserved region of rat EFP1 comprises a putative thioredoxin domain with an inactive catalytic site and an adjacent region that is in good agreement with the thioredoxin fold. 40 The second conserved region of the rat EFP1 protein also contains a putative thioredoxin domain but harbors a catalytically active CXXC motif ( 787 CGFC 790 ). The presence of two putative thioredoxin domains and the similarity in protein domain structure suggest that EFP1 is a member of the PDI family, a growing family of ER proteins that display isomerase, chaperone and calcium binding properties. 41, 42 The founding member, PDI, possesses the domain structure a-b-b'-a'-c, with a and a' representing the catalytically active thioredoxin domains, b and b' the thioredoxin-like domains and c the calcium binding domain. The b' domain has been implicated in substrate binding, whereas the b domain appears to have a rather structural function. 41 For full catalytic The novel Par-4 interaction partner eFP1 is upregulated during eR stress Dovepress submit your manuscript | www.dovepress.com Dovepress activity, all thioredoxin-like domains of PDI are required. 43 In comparison, rat EFP1 contains the domain structure a-bx-a'-CC/LZ, where CC/LZ represents the coiled coil and the leucine zipper domain and x an uncharacterized domain or a linker region ( Figure 1A) . Although no high sequence or structural similarities were identified between the x domain of rat EFP1 and the b' domain of PDI, the similar domain position suggests a possible function in substrate binding. Some of the PDI family members, like ERp29, possess a C-terminal alpha helical D domain that seems to be involved in substrate processing. 42, 44 However, the C-terminal coiled coil domain of rat EFP1 shows no sequence identity with the D-domain of the other PDI family members, arguing that this protein-protein interaction domain is unique for EFP1.
Analysis of the expression of EFP1 at the transcriptional level revealed a ubiquitous expression in various rat tissues, whereas no EFP1 transcript could be detected in rat skeletal muscle. Additionally, EFP1 is ubiquitously expressed in several tumor cell lines. Ectopic expression and immunostaining of rat EFP1-GFP and EFP1-Myc fusion proteins showed that the proteins reside in the ER as it has been demonstrated for the human ortholog. 26 Unfortunately, no specific EFP1 antibodies are available to demonstrate the subcellular localization of the endogenous EFP1 protein. However, the presence of an ER signal anchor and the structural similarities with the members of the PDI protein family supports the ER distribution of the EFP1 protein. Furthermore, by employing an insulin disulfide reduction assay, we demonstrated that the purified recombinant EFP1 protein possesses catalytic activity and that the catalytic activity is dependent on the active site motif 787 CGFC 790 located in the second thioredoxin domain of EFP1. The kinetics of the reaction with EFP1 showed a slower rate compared to recombinant purified thioredoxin from E. coli. Yet, it has to be taken into consideration that EFP1, like other thioredoxin-related proteins, might be involved in various redox regulations (eg, oxidation, isomerization). The catalytic activity of EFP1 was not completely abolished after substitution of the cysteine residues to serine residues in the active site CXXC motif; therefore it is likely that the catalytic activity of EFP1 only partially involves reduction activity. Our results are in good agreement with a previous report of Horibe and colleagues, 45 showing that the PDI family member PDIr retained over 50% of oxidative refolding activity towards α 1 -antitrypsin after exchanging all six catalytic site cysteine to serine residues.
We demonstrate in this study that EFP1 is a glycoprotein and that the glycosylation is of the high mannose type typical for ER-resident proteins. We do not know whether the highly glycosylated 155-kDa form of EFP1 represents the mature active protein. It has been reported that the highly glycosylated 190-kDa form of the EFP1 interaction partner Duox corresponds to the mature active protein expressed at the plasma membrane and that the high mannose 180-kDa form corresponds to the immature inactive protein which resides in the ER. 26 Likewise, the ectopically expressed EFP1 protein could represent a less active protein compared to the endogenous EFP1 protein.
The expression of EFP1 was upregulated at the transcriptional level upon treatment of cells with agents that induce ER stress, but not by agents that induce oxidative stress or ER-independent apoptosis. Thus, EFP1 is specifically upregulated during ER stress, as it has been shown for a number of ER chaperones, including many members of the PDI family. 46 Our findings suggest that EFP1 may function as a cell-protective enzyme and corroborate the assumption that EFP1 is a member of the PDI family. Unfortunately, no specific EFP1 antibodies are available to examine the upregulation of EFP1 after ER stress at the protein level. Clearly, this issue requires further investigation.
We have identified the rat ortholog of EFP1 in a yeast two-hybrid screen in search for new interaction partners of Par-4 that might serve as regulators or targets in Par-4-mediated apoptosis. The interaction between Par-4 and EFP1 was confirmed by pull-down experiments, dot blot analysis and co-immunoprecipitation experiments. These experiments corroborated a physical interaction of both proteins, although ectopically expressed EFP1-GFP and FLAG-Par-4 did not colocalize in the transfected cells. It has been demonstrated that many members of the PDI family and other ER proteins like calreticulin are not only localized in the ER but also in non-ER locations. 47 PDI itself has been found in the nucleus 48 as well as outside of the cell, either attached to the cell surface or in a secreted form. 49 Overexpressed ERp57 was shown to be secreted from cultured cells 50 and has been detected both in the cytosol 51 and in the nucleus. 48 The mechanism by which proteins of the PDI family can escape from the ER is unknown. It is therefore possible that by a similar mechanism, EFP1 can escape from the ER and interact with Par-4 in the cytoplasm to control the function of Par-4 after induction of ER stress. Despite the well-established apoptotic action of Par-4, our understanding of molecular mechanisms controlling Par-4 function is limited. To date, only two regulatory mechanisms are known: the upregulation of Par-4 gene transcription, 20, 52 and the phosphorylation within the 59-residue core region, termed selective for apoptosis induction in cancer cells (SAC) 53 at the critical phosphorylation site T164/T155 (human and rat amino acid sequence, respectively). However, other regulatory mechanisms are likely to exist, since Par-4 is expressed in various tissues and cell lines without inducing apoptosis or sensitizing the cells for apoptosis. The novel Par-4 interaction partner EFP1 is a good candidate to regulate the function of Par-4 since i) coexpression of Par-4 and EFP1 in CHO cells resulted in enhanced Par-4-mediated apoptosis and ii) EFP1/Par-4-mediated apoptosis is dependent on the catalytic activity of EFP1. How EFP1 exerts its regulatory function on Par-4 remains elusive. It is tempting to speculate that EFP1 might function as a molecular chaperone or disulfide isomerase which can induce a conformational change of the Par-4 protein resulting in enhanced Par-4 activity. Indeed, the amino acid sequence of the rat Par-4 protein contains three cysteine residues at the position 82, 103, and 165 which are able to form disulfide bonds to stabilize the tertiary and/or quaternary structure of the protein.
As a potential regulator of Par-4, EFP1 provides a link between ER stress and Par-4-induced apoptosis. Par-4 has been suggested to play a significant role in ER stress-induced apoptosis in Alzheimer's disease, 19 and deregulated expression of Par-4 has been implicated not only in Alzheimer's disease, [54] [55] [56] [57] but also in amyotrophic lateral sclerosis (ALS), Parkinson's disease and ischemic neuronal death. [58] [59] [60] [61] Furthermore, we could show in this study that Par-4 might play an important role in Ca 2+ stress-mediated apoptosis, since the induction of apoptosis in the ionomycin and thapsigargin treated cells were significantly decreased after siRNA oligonucleotide-mediated knockdown of Par-4. That the siRNA oligonucleotide-mediated knockdown of Par-4 had no effect on apoptosis induction after treatment of the cells with the glycosylation inhibitor tunicamycin might be explained by the fact that EFP1 is a glycoprotein and thus, tunicamycin might hamper the function of EFP1 and Par-4.
Therefore, we propose a hypothetical model how EFP1 and Par-4 might determine the cell fate during ER stress (see Figure 6 ). In the presence of low Par-4 levels, EFP1 may act as a molecular chaperone or disulfide isomerase and contribute to restore the ER function (left part of Figure 6 ). If the ER stress response fails to restore the ER function, a disturbed calcium homeostasis ("Ca 2+ stress") might be the consequence, leading to transcriptional upregulation of Par-4 as has been shown by Sells and colleagues and by Hsu and colleagues 20, 52 and to the induction of apoptosis. In the presence of high Par-4 levels, EFP1 may function as an activator of Par-4, thus enhancing Par-4-mediated apoptosis (right part of Figure 6 ). According to our model, Par-4 itself is not fully active until ER stress and upregulation of EFP1 occurs. Once fully activated by EFP1, Par-4 induces apoptosis.
By identifying EFP1 as a novel interaction partner and potential regulator of Par-4, we provide a missing link between Par-4 and ER stress, elevated intracellular calcium levels, and the induction of apoptosis. Detailed analysis of the EFP1-Par-4 interplay might therefore yield valuable insights into the regulatory mechanisms of ER stress and apoptosis. 
